There are about 36818 clinical studies being (or have been) conducted in China. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
To examine the effects of a health Education Intervention based on the Behaviour Change Wheel (BCW) theory on fear of hypoglycemia and relevant outcomes of type 2 diabetic patients.
This study will retrospectively include LST patients who were admitted to 6 medical centers (The Second Affiliated Hospital, College of Medicine, Zhejiang University; The Affiliated Jinhua Hospital, Zhejiang University School of Medicine; First Affiliated Hospital of Huzhou University; The Second Hospital of Jiaxing; Jinhua People's Hospital; Lanxi People's Hospital) from 2020.05.01 to 2023.04.30 with the purpose of comparing the efficacy and safety of hybrid ESD and ESD in the treatment of colorectal LST. The complete resection rate, operation time, operation cost, intraoperative and postoperative complications of hybrid ESD and ESD LST will be compared. To provide strong evidence for the selection of endoscopic treatment strategies for LST.
Explore the effectiveness and safety of emergency endovascular treatment in patients with mild ischemic stroke due to acute large vessel occlusion in the anterior circulation, identified through perfusion imaging.
The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Forel's Field H as adjunctive therapy for alleviating symptoms in Lennox-Gastaut Syndrome.
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic disease)，and to evaluate the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (without symptomatic dysphagia or oligometastatic disease).
Chemotherapy, immune checkpoint inhibitors, and anti-angiogenic targeted therapies have been explored in combination for neoadjuvant and conversion therapies. However, the efficacy of the novel anti-angiogenic agent fruquintinib in combination with immune checkpoint inhibitors and chemotherapy in the neoadjuvant and conversion treatment of locally advanced or metastatic gastric cancer has not been reported. This study aims to observe the efficacy and safety of fruquintinib combined with immune checkpoint inhibitors and chemotherapy in real-world settings.
The aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's （B-NHL） lymphoma. The main questions it aims to answer： 1. The safety of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells in B-NHL; 2. The effect of different doses of bispecific antibody maintenance therapy on CAR-T cell expansion.
With the advancement of sports science, Post-Activation Potentiation (PAP) has become a focal point of research, garnering significant attention for its underlying physiological mechanisms. Current studies suggest three primary mechanisms: 1) phosphorylation of myosin regulatory light chains (RLCs); 2) increased recruitment of high-threshold motor units; and 3) a reduction in sarcomere length heterogeneity within muscle fibers due to pre-stimulation (Liu & Li, 2017). These mechanisms collectively contribute to an effect known as Post-Activation Performance Enhancement (PAPE), which significantly enhances muscle strength and explosiveness shortly after activation (Blazevich & Babault, 2019). During the activation process of motor units with increasing loads, low-threshold motor units are recruited first, followed by high-threshold motor units. As the load increases, the root mean square (RMS) value increases linearly, further promoting the overlap of motor unit potentials and the rise in RMS values. This overlap in activation timing among adjacent motor units results in greater overall muscle force output (Liu, 2008; Tian, 2009). The significance of this lies in the fact that as the degree of muscle activation increases, especially under incremental loads, the muscle's ability to adapt to subsequent strength or explosive tasks may be enhanced. In competitive sports, optimizing the relationship between warm-up and performance is crucial. Research indicates that the duration of PAPE varies with individual differences, training type, intensity, and recovery intervals. The characteristics of the PAPE effect also differ. Additionally, following constant loads, the enhancement and decay rates of performance in PAPE show varying rates at different times, and these rates do not exhibit a symmetrical linear change in absolute value (Liang, M 2020; Guo, W et al. 2018; Liu, R and Li, Q. 2017). The competition pace in sports demands precise modulation of performance enhancement rates after activation, and athletes can leverage these characteristics by selecting appropriate loading forms to trigger PAPE at critical moments in competition. To explore the enhancement or decay rates of performance over different time domains, our research team designed a protocol consisting of incremental loads.
This is an open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects
This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy (docetaxel+cisplatin+5-fluorouracil, DCF) in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma.